- Home
- AR vs BBIO Comparison
AR vs BBIO Comparison
Compare AR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AR
- BBIO
- Stock Information
- Founded
- AR 2002
- BBIO 2015
- Country
- AR United States
- BBIO United States
- Employees
- AR N/A
- BBIO N/A
- Industry
- AR Oil & Gas Production
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- AR Energy
- BBIO Health Care
- Exchange
- AR Nasdaq
- BBIO Nasdaq
- Market Cap
- AR 9.9B
- BBIO 10.4B
- IPO Year
- AR 2013
- BBIO 2019
- Fundamental
- Price
- AR $30.91
- BBIO $62.64
- Analyst Decision
- AR Buy
- BBIO Strong Buy
- Analyst Count
- AR 16
- BBIO 18
- Target Price
- AR $43.73
- BBIO $73.89
- AVG Volume (30 Days)
- AR 4.4M
- BBIO 2.7M
- Earning Date
- AR 10-29-2025
- BBIO 10-29-2025
- Dividend Yield
- AR N/A
- BBIO N/A
- EPS Growth
- AR N/A
- BBIO N/A
- EPS
- AR 1.87
- BBIO N/A
- Revenue
- AR $5,007,754,000.00
- BBIO $353,780,000.00
- Revenue This Year
- AR $24.16
- BBIO $115.12
- Revenue Next Year
- AR $6.58
- BBIO $65.29
- P/E Ratio
- AR $16.54
- BBIO N/A
- Revenue Growth
- AR 17.21
- BBIO 62.46
- 52 Week Low
- AR $25.36
- BBIO $21.72
- 52 Week High
- AR $44.02
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- AR 41.90
- BBIO 64.23
- Support Level
- AR $29.10
- BBIO $52.75
- Resistance Level
- AR $33.06
- BBIO $69.48
- Average True Range (ATR)
- AR 1.10
- BBIO 2.86
- MACD
- AR -0.16
- BBIO 0.81
- Stochastic Oscillator
- AR 44.58
- BBIO 59.12
About AR Antero Resources Corporation
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2024, the company reported proven reserves of 17.9 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,424 million cubic feet of equivalent a day in 2024 at a ratio of 35% liquids and 65% natural gas.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.